Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands
Published in: Haematologica
Access to document
10.3324/haematol.2020.247536
document
Matthijs van der Meulen, Jacoline E C Bromberg, Marcel Nijland, Otto Visser, Jeanette K Doorduijn, Avinash G Dinmohamed
Machine Learning in the Differentiation of Follicular Lymphoma from Diffuse Large B-cell Lymphoma with Radiomic [18F]FDG PET/CT Features
Filipe Montes de Jesus, Yunchao Yin, Elissavet Mantzorou-Kyriaki, Xaver Kahle, Robbert de Haas, Derya Yakar, Andor W.J.M. Glaudemans, Walter Noordzij, Thomas Kwee, Marcel Nijland
Machine Learning in the Differentiation of Follicular Lymphoma from Diffuse Large B-cell Lymphoma with Radiomic [18F]FDG PET/CT Features
Filipe Montes de Jesus, Yunchao Yin, Elissavet Mantzorou-Kyriaki, Xaver Kahle, Robbert de Haas, Derya Yakar, Andor W.J.M. Glaudemans, Walter Noordzij, Thomas Kwee, Marcel Nijland
Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-020-04022-5
document
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
Published in: Haematologica
Access to document
10.3324/haematol.2019.238162
document
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) compared to patients withoutMYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL. A phase II trial was conducted evaluating the efficacy of lenalidomide (15 mg day 1-14) in combination with R-CHOP (R2CHOP) in...
Martine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous, Pieternella J Lugtenburg, Daan Dierickx, Gustaaf W van Imhoff, Joost S P Vermaat, Erik A F Marijt, Otto Visser, Caroline Mandigers, Yavuz M Bilgin, Aart Beeker, Mark F Durian, Bas van Rees, Lara H Bohmer, Lidwine W Tick, Rinske S Boersma, Tjeerd J F SnijdersHarry C Schouten, Harry R Koene, Eva de Jongh, Nathalie Hijmering, Arjan Diepstra, Anke van den Berg, Anne I J Arens, Julia Huijbregts, Otto Hoekstra, Josee M Zijlstra, Daphne de Jong, Marie José Kersten